| scholarly article | Q13442814 |
| P2093 | author name string | Li Zhang | |
| Fang Wang | |||
| Bei Zhang | |||
| Gui-Fang Guo | |||
| Fei-Fei Zhou | |||
| Hui-Juan Qiu | |||
| Liang-Ping Xia | |||
| Wen-Zhuo He | |||
| Pi-Li Hu | |||
| Xu-Xian Chen | |||
| P2860 | cites work | Journal of Clinical Oncology | Q400292 |
| Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. | Q46942430 | ||
| Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. | Q51675909 | ||
| Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. | Q54799349 | ||
| Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts | Q70487549 | ||
| Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells | Q72808513 | ||
| Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study | Q80100963 | ||
| A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC) | Q83284544 | ||
| [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases] | Q84512788 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 | ||
| Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis | Q33530754 | ||
| Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. | Q33722621 | ||
| Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy | Q36011603 | ||
| Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. | Q37681223 | ||
| Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer | Q40493345 | ||
| Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer | Q43184359 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study | Q46347493 | ||
| Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer | Q46772387 | ||
| Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer | Q46843394 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| Asian people | Q4058325 | ||
| P304 | page(s) | S570-6 | |
| P577 | publication date | 2010-10-22 | |
| P1433 | published in | Medical Oncology | Q2152666 |
| P1476 | title | Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases | |
| P478 | volume | 28 Suppl 1 |
| Q35538759 | Feasibility of cetuximab and chemoradiotherapy combination in Chinese patients with unresectable stage III non-small cell lung cancer: a preliminary report | cites work | P2860 |
Search more.